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 Abstract 
AIMS: Patient reported outcomes (PROs) are a distinctive method of evaluating patient’s 
response to health care or treatment. This study aimed to analyse the impact of PROs in 
patients on DOAC treatment, prescribed for any indication (e.g.  VTE treatment or AF) using 
controlled trials (CT) and real world observational studies (OS).  
METHODS: A systematic search of articles was conducted according to PRISMA guidelines 
using databases, with the last update in November 2018. The Cochrane Collaboration tool for 
assessing bias in RCTs and the Newcastle-Ottawa Scale adapted for cross-sectional studies 
were used. Outcomes evaluated were related to Health Related Quality of Life (HRQoL), 
satisfaction, adherence and compliance.  
RESULTS: Twenty-one original studies (CT=6 & OS=15) were included. HRQoL was assessed by 
6 (CT=1 & OS=5) studies and reported that HRQoL scores were similar in patients on DOACS 
and warfarin. patients prescribed DOACs presented higher HRQoL scores which were 
attributed to lack of intense monitoring required compared with warfarin but this was not 
statistically significant. The majority of studies (CT=5 & OS=9) investigated patient reported 
satisfaction indicating greater satisfaction with DOACs with significantly lower burden and 
increased benefit scores for patient on DOACs. Patient reported expectations, compliance 
and adherence were similar for patients on DOACS and warfarin.  
CONCLUSION: Patients appear to prefer treatment with DOACS versus warfarin. This has been 
exhibited by the higher QoL, satisfaction and adherence described in the studies. However, 
heterogeneity in the analysed studies does not allow firm conclusions.  
 
 
 
 
 
 
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT 
Direct Oral Anticoagulants have revolutionised treatment of VTE and prevention of stroke due 
to AF with demonstrated similar efficacy and safety as warfarin. PROS are an optimum 
method of evaluating patients’ perceptions of these agents.  
WHAT THIS STUDY ADDS 
Patients report higher satisfaction, adherence and enhanced quality of life with DOACs 
compared to warfarin therefore indicating a higher preference for these agents.  
Introduction  
Inception of new (or direct) oral anticoagulants (NOACs or DOACs) have bought a new dawn 
to the treatment of thromboembolic conditions such as non-valvular atrial fibrillation and 
treatment or prophylaxis of venous thromboembolism (deep vein thrombosis, (DVT) and 
pulmonary embolism, PE). These direct oral anticoagulants  (e.g. apixaban, rivaroxaban, 
dabigatran and edoxaban) have made rapid progress in revolutionising anticoagulation and 
been extensively investigated and researched in clinical trials for their clinical effectiveness 
and safety profile in comparison with standard treatment 1.  
Anticoagulation with warfarin, a potent vitamin K antagonist, has been the mainstay of 
treatment for prophylaxis, treatment and long-term management of thromboembolic 
conditions such as venous thromboembolism (VTE) atrial fibrillation (AF) and stroke. Use of 
warfarin effectively is associated with a significant reduction in the risk of stroke and mortality 
associated with AF 1. However, warfarin use is limited by its narrow therapeutic index 
requiring regular monitoring of INR, multiple drug interactions and dietary restrictions 2. Over 
the past decade, the introduction of DOACs, have revolutionised the treatment of these 
conditions without the complications associated with warfarin. DOACs have also been 
recognised as a safe and effective treatment option in thromboprophylaxis post orthopaedic 
surgery. However, these agents have been known to carry a potential risk of bleeding with no 
actual method of anticoagulation reversal 3,4.  
DOACs have been accredited with reducing complications which arise through monitoring and 
individual-dosing of VKAs.  Dabigatran was first approved for use within the UK for AF and VTE 
in 2011 following results of the RELY trial 5. Rivaroxaban approval followed showing non-
inferiority to warfarin for the prevention of AF and VTE in the ROCKET AF study in 2011 6. The 
ARISTOTLE trial led to the licensing of apixaban in 2012 showing that apixaban was superior 
to warfarin in preventing stroke in AF patients and VTE 7. Edoxaban was approved in 2015 
after the result of the ENGAGE-AF trial displaying non-inferiority of edoxaban to warfarin 8. 
These clinical studies emphasised the clinical efficacy of the DOACs versus warfarin with the 
enhanced benefit of a reduced intracranial and major bleeding however showed a higher risk 
of GI bleeding. Nevertheless, the European society of Cardiology and NICE have 
recommended DOACs as a suitable option for non-valvular AF over warfarin 9,10.  
Patient-reported outcomes (PROs) are testimonies from the patient about how they feel 
about any particular condition or treatment they are receiving without any intervention or 
bias from the clinicians 11. PROs include any evaluation of treatment or outcome directly from 
patient interviews, questionnaires or specifically developed tools to capture and enable 
analysis of valuable patient-reported data. PROs provide valuable data from the patient’s 
perspective and are sometimes used as primary outcomes from clinical trials. However, more 
often PROs are conveyed as sub-analyses after the initial trials have been published 12.   
PROs are subjective measures relating to patent experience and quantify assessment of 
patient satisfaction, adherence or health related quality of life (HRQoL) 13. HRQoL can be 
defined as an evaluation of impairment, disability or handicap 12,14. Patient satisfaction 
determines perceived burden or benefits of the perceived treatment being appraised 12.  
The Anti-clot Treatment Score (ACTS), Treatment Satisfaction Questionnaire for Medication 
(TSQM) and Perception of Anticoagulation Questionnaire (PACT) are tools used to assess 
satisfaction 15-17. The Duke Anticoagulation Satisfaction Scale has been specifically developed 
to measure both satisfaction and HRQoL 18,19. Patient reported adherence can be evaluated 
using self-report scales such as the Morisky 4 or 8-item adherence scale 20. These tools 
measure disease or treatment-specific objectives describing severity of symptoms, benefit, 
adverse drug effects in order to capture the patients’ well-being and experience with the 
intervention. Such tools have been developed to measure PROs in patients receiving 
anticoagulation and have been scrutinised and validated prior to use. 
A recent systematic review by Generalova et al explored clinicians’ views and experiences of 
DOACs in patients with AF presenting evidence  of clinican preference in recommending 
DOACS as first choice for these patients 21. However, publishing/ reporting of PROs from 
clinical trials have been limited and to date there are no systematic reviews conducted which 
evaluate or cumulatively analyse the results of PROs in patients prescribed DOACs. This 
systematic review aims to bridge this gap in knowledge and enhance understanding of PROs 
in anticoagulation with DOACs. The aim of the current review is to systematically assess the 
PROs reported by adults receiving DOACs, with additional focus on patient satisfaction, 
adherence, compliance and health-related quality of life (HRQoL) using original studies 
(controlled trials and observational real-world studies). 
Methods 
Scope of review: eligibility criteria  
The systematic review process was conducted following PRISMA guidelines 22. The primary 
investigator (SKA) applied the eligibility criteria to examine abstracts of original journal 
articles published in English that (a) Patient Reported Outcomes (PROs) and (b) new or direct 
oral anticoagulants (DOACs) namely apixaban, rivaroxaban, dabigatran or edoxaban were 
included. Finally, abstracts had to report PROs based on a recognized PRO tool with 
measurable outcomes.  The following types of studies were excluded: review articles, 
observational studies and articles on compliance or persistence which focussed on tablet 
count or prescription monitoring.  
 
For population attributes, studies that were included that assessed PROs in adults being 
treated with a DOAC. The search was restricted to: studies involving humans and original 
journal articles. Titles and abstracts were screened to remove studies that were irrelevant to 
the aim of the review and full texts of the remaining studies that analysed the required data 
but did not utilise a recognised PRO tool were excluded.  
Information sources 
The following databases were searched between September 2018 and October 2018 with no 
filters set on publication date: PubMed (United States National Library of Medicine), 
Cumulative index to Nursing and Allied Health Literature (CINAHL – Elsevier, Amsterdam, 
Netherlands), MEDLINE (Medical Literature Analysis and Retrieval System Online, or 
MEDLARS Online), Embase (Excerpta Medica database) from 1974 until September 2018, 
SCOPUS and Springer Link databases.  Google scholar was also searched to identify articles 
not indexed in scientific databases. References cited in the reference list of each identified 
original research were scanned for any additional articles that would be relevant to this 
review; these were subsequently also scanned for reviews and studies which may have been 
relevant and which were subject to the same eligibility evaluation. 
 
Searching 
The search strategy identified original research on patient-reported outcomes associated 
with the use of new or direct oral anticoagulants. Search terms were constructed using a 
Population (P), Intervention (I), Outcome (O) model and considered the following strategy 
limited to ‘‘adults (limit: 18+ years), humans and English language”. Search terms were 
Anticoagulant* OR oral anticoagulant* OR novel oral anticoagulant* OR Non Vitamin K 
antagonist oral anticoagulant* (NOAC) OR vitamin K antagonist oral anticoagulant* OR 
coumarin* OR dabigatran OR rivaroxaban OR apixaban OR edoxaban OR warfarin OR direct 
factor Xa inhibitor* OR direct thrombin inhibitor* AND Patient reported outcomes OR patient 
reported satisfaction OR patient reported adherence OR quality of life.  
 
Study selection 
After possible studies were identified, all retrieved titles were screened by the primary 
investigator (SKA) to determine their potential relevance. The assessed abstracts were 
independently by another investigator (SSH) against five inclusion criteria: (i) original research 
studies; (ii) recognised and validated tool to measure PROs; (iii) patients were taking a DOAC 
for >4 weeks; (iv) adult subjects (≥19 years of age); and (v) reported in English. Full papers 
from potential studies were independently assessed by the investigators (SKA and SSH). 
 
Data collection process 
All studies selected for this systematic review were screened by two reviewers independently 
to validate the results. The purpose, study design, number of participants, description of 
observations, and outcome measures were recorded. The data from all the retrieved studies 
were subsequently collected and tabulated using a form developed by the lead author that 
was verified by the second reviewer. Extracted information from studies is mentioned in Table 
1. The extracted information included study design, study participants and settings, objectives 
of the study, response rate and sample size, outcomes measured, summarized results and 
main findings of the study.  
Classification of Outcomes 
The outcome measures were categorized into 3 main groups, namely health related quality 
of life (HRQoL), patient reported satisfaction and patient reported adherence/ compliance or 
expectations related to anticoagulation treatment with DOACs.   
 
 
 
Assessment of quality and risk of bias in included studies  
The lead author independently assessed the risk of bias of each of the included studies and 
discussed their assessments with other two authors to achieve consensus. The six-item risk 
of bias assessment was used as it is a validated method of analysing bias within randomised 
controlled trials 11,23. The criteria for judging include random sequence generation of the 
study sample, allocation concealment, blinding of participants and personnel, blinding of 
outcome assessment, incomplete outcome data, selective reporting and other issues which 
may indicate bias. The modified Newcastle-Ottawa Scale was selected because it was easier 
to use and considered reliable to measure biasness in cross-sectional studies 24. Each of the 
selected cross-sectional studies was evaluated for selection, comparability and outcome bias. 
The lead author rated each paper using the NOS assessment methods for selecting study 
participants, methods to control confounding, using appropriate statistical methods and 
methods for measuring outcome variables.  
  
Results 
Search Results and Study Characteristics  
The search yielded 3285 unique titles (1964 from PubMed, CINAHL, Medline and EMBASE 
with an additional 1321 titles from SCOPUS, Springer Link and Google Scholar). After removal 
of duplicate records, 3231 abstracts were screened. Of these, 3,104 studies were excluded. 
Of the remaining 127 articles, 97 were excluded as they did not describe original research or 
did not illustrate patient reported outcomes or focussed on warfarin alone. The search 
yielded 11 articles which were excluded because they involved investigations on adherence 
or persistence based on pill taking patters, tablet counting or prescription fill analysis rather 
than patient reported outcomes. A total of 21 studies were ultimately included in the review, 
6 controlled trials and 15 observational studies (Figure 1).  The 21 studies evaluated patient 
reported outcomes or quality of life, using a validated tool, associated with the use of DOACs. 
The controlled trials (n =6) included 5 randomized and 1 non-randomized trial (see Table 1). 
Controlled trials were used as they provide larger scale trials within controlled environments 
however due to being sponsored by industry often may contain an element of bias and not 
present the full patient overview. Real-world observational and cross sectional studies 
provide actual patient experience and use of the treatment in practice. Of the 6 controlled 
trials, 5 were conducted in multiple countries (including UK, US, Canada, Netherlands, France, 
Germany and Italy) 25-29 and one was conducted in Japan 30. The observational studies (n = 15) 
used the following study designs: 11 prospective studies conducted in Spain, France, Canada, 
Japan, US, Australia and Europe.  Four of the studies were cross-sectional studies conducted 
in Spain, France and Canada (see Table 1).  
Risk of Bias Within Studies  
In the case of controlled trials, 5 studies used randomized methods to generate the sequence 
25-28,30, and 1 study used some form of data checking for patient selection (see Table 2) 29. 
However, only 3 studies clearly described a form of concealed allocation and personnel and 
participant blinding 25-27. Hence, none of the studies satisfied all 6 key criteria together23. In 
respect to the observational studies, the NOC scale was used for quality assessment (see 
Table 3). Of the 15 observational studies, 6 were good studies with a score of 7-8 points 31-35. 
Eight of the studies were regarded as satisfactory studies with a score of 5-6 points 36-43. Only 
one study was considered as an unsatisfactory study with a score of only 4 points due its 
absence of the use of a validated PRO tool 44.  Quality issues often lacking were blinding of 
the outcome assessment, identification of potential confounders, assessment of the subjects’ 
likelihood of the outcome upon enrolment, and validity and reliability of the outcome 
assessment tools.  
Study Outcomes  
HRQoL was reported in five studies and used the  Euro-QoL utility and visual analog scores 
which covered 5 dimensions (consisting of mobility, autonomy, usual activities, 
pain/discomfort, anxiety/ depression) or the Sawicki questionnaire (which is a 32 items 
questionnaire grouped covering general treatment satisfaction, self-efficacy, strained social 
network, daily hassles and distress) 14,45,46.  The majority of the studies (14 studies) described 
patient reported treatment satisfaction which had been measured using the Anti-Clot 
Treatment Scale (ACTS) (a 15 point scale to score burden and benefit) or treatment 
satisfaction questionnaire for medication version II (TSQM VII which assess 4 subscales of 
convenience, effectiveness, global satisfaction and side effects based on Likert scales) 15,16. 
Medication-related, review or intervention-related, and adverse outcomes. Overall, the 
outcomes were diverse with differing definitions, methods of data collection, varying time 
points, and different reporting methods. 
 
Patient Reported Satisfaction   
Greater satisfaction with DOACs was reported in five of the included studies using the ACTS 
tool. These studies showed a significant reduction in the burden score and a  higher benefits 
score illustrating  more satisfaction with DOAC treatment 26,27,29,37,38,43. One study 
demonstrated a reduced ACTS burden score but stable or no change in the benefit score 30,39.  
Only two studies showed increased satisfaction in the DOAC group based on the PACT Q2 tool 
32,40. Another study which used the PACT Q2 tool showed high satisfaction in both 
anticoagulation groups, VKA and DOAC 33. One of the studies reported inconclusive results or 
dissatisfaction with DOAC therapy however these patients had been switched from warfarin 
and the questionnaire may correlate to the patients’ experiences of warfarin treatment 36. 
Three of the studies which utilised the TSQM questionnaire reported greater patient 
satisfaction with DOAC treatment scores 27,28,30. Okumura et al 43 reported no difference in 
satisfaction when utilising the TQSM score. Stephenson et al 35 used the Duke Anticoagulation 
treatment scale which confirmed patient satisfaction with DOAC treatment.  Satisfaction with 
VKA versus DOAC was also analysed by Contreras Muruaga et al 42 however the patient 
population was the same as another study 37 and therefore these results were excluded from 
this review to avoid duplication.  
Health Related Quality of Life (HRQoL) 
HRQoL was investigated by 6 different studies, which utilised either the Euro Qol 5 dimension 
of the Sawicki questionnaires. All 6 studies reported that HRQol was similar among patients 
on VKA and DOACs 25,31-33,41,42. Contreras Muruaga et al 42 demonstrated that a higher QoL 
was associated with longer time in therapeutic range and better INR control. Four of the 
studies described a higher HRQoL score in the DOAC group but this was not statistically 
significant 31-33,41.  Keita et al. 33 showed that this higher QoL score can be attributed to the 
lack of blood monitoring associated with DOACs. Marques-Contreras et al., 41 highlighted that 
a significantly higher QoL score was confirmed in patients with established compliance after 
12 months of treatment.    
Patent Reported Expectations, Compliance or Adherence  
Larochelle et al.40 used the perception of anticoagulation treatment questionnaire  to 
determine patient expectation with anticoagulation treatment prior to initiation. The study 
found that there was no statistically significant difference between the groups however there 
was a greater expectation of adverse effects in the warfarin group.  
Patient reported compliance was explored by Carrothers et al. 44 using an investigator 
developed questionnaire and  showed that the majority of patients prescribed rivaroxaban 
were complaint with   treatment.  
Patient reported medication adherence was investigated by 5 studies using the 8 point 
Morisky Medication Adherence Scale (MMAS-8) 32-35. Castellucci et al. 47 used an abridged 4 
point version of the MMAS  tool.  All 5 studies indicated that adherence was similar among 
patients treated with VKA and DOACs. Obamiro et al., 34 highlighted that a higher adherence 
score was observed in the patient group which exhibited a higher knowledge of 
anticoagulation treatment.  
Discussion 
This systematic review provides the first overview of the use of PROS in anticoagulant 
treatment and has categorised an increasing body of evidence to establish the importance of 
PROs in patients treated with DOACs. The systematic search for this review yielded 21 articles 
(6 controlled studies and 15 observational studies) from 3231 screened articles. The studies 
focussed on PROs such as patient-reported satisfaction, expectations, compliance and 
adherence as well as health-related quality of life. The majority of the studies described 
enhanced satisfaction in patients prescribed DOAC treatment using self-report scales. Studies 
highlighting patient reported expectations, adherence and compliance using the MMAS-8 
tool showed that adherence was similar in both DOAC and warfarin groups however patients 
prescribed warfarin had more expectations of adverse events. It was identified that patients 
with greater knowledge of their anticoagulant treatment were more like to adhere. HRQOL 
was investigated by some studies which demonstrated that there was no significant 
difference between the two groups. Increased HRQoL was observed in the DOAC group for a 
couple of studies however this was not statistically significant. in contrast a reduced HRQol is 
observed in patients prescribed warfarin which correlates to poor INR control, a factor which 
does not influence DOAC treatment 48.    
Although DOACS are not associated with the same pharmacokinetics or pharmacodynamic 
issues as warfarin, they have presented with additional concerns surrounding medication 
adherence and therapeutic efficacy. Hence, PROs are a beneficial outcome measure in order 
to determine patient satisfaction, adherence and compliance with DOAC treatment. PROs 
offer a unique perspective of treatment effectiveness without the invasive blood testing and 
monitoring requirements associated with warfarin. These can often be more reliable that 
physiological parameters and informal interviews through the use of optimal validated tools 
as a method of categorising and measuring patient outcomes 49.  
Warfarin and DOACs are equally as effective in the prevention or treatment of VTE and stroke 
50. DOACs are associated with less bleeding risk and net benefit when compared to warfarin 
51. However, the simple medication regime and lack of therapeutic monitoring associated with 
DOACS are likely to result in more patients and physicians opting and preferring DOAC 
treatment with proven satisfaction, adherence and likely HRQoL. Satisfaction has been 
reported with warfarin treatment which comprises less complicated regimes and monitoring 
and management methods including self-monitoring, pharmacist inclusion or single point of 
testing at home 52-54.  
Near patient testing and self-monitoring with warfarin have shown improved satisfaction 
rates than standard clinic monitoring with warfarin treatment. Studies have shown an 
improved quality of anticoagulation in patients who self-monitor and self-adjust their doses 
which results in an overall reduced incidence of VTE by around 50%, a 33% reduction in major 
haemorrhage and a reduction in mortality from all causes 55.   
The World Health Organisation has reported that half of the patients prescribed regular 
medication for chronic illness do not adhere to their prescribed regimes 56. Factors which 
affect adherence are multiple and complicated in nature. Factors of non-adherence can be 
patient-related (lack of literacy, involvement or engagement), physician-related (prescribing 
of complex regimens or ineffective communication) or can be healthcare system related 56. 
Barriers to adherence and medication taking behaviour is complex and challenging to 
overcome therefore patient satisfaction to treatment plays a fundamental role in enhancing 
patient concordance, experience and overall preference for taking their medications for 
chronic conditions. Further evidence suggests that enhanced patient knowledge about 
anticoagulation treatment results in enhanced patient satisfaction therefore pharmacist are 
best placed experts in medicines to provide thorough counselling to patient through effective 
communication 57-59.  
Therefore, healthcare professionals play an elemental role in educating and motivating 
patients to engage with their treatment plan to ensure maximum adherence with medication. 
Empowering and motivating patients as well as involving them in the decision making process 
is likely to provide profound benefit to the patient and overall healthcare economy due to 
reduced incidence of complications and costly hospitalisations. The European Heart Rhythm 
Association (EHRA) have issued a consensus statement which also highlights the importance 
of patient education an a vital element in the management of cardiac arrthytiams including 
AF. EHRA suggests that all patients should receive individualised and specially desgined 
information which is specific to their needs, condition and treatment and repeated over time 
60. A clear link has been established between greater treatment satisfaction resulting in 
enhanced adherence to treatment for chronic conditions 61. Patients reporting greater 
satisfaction, improved quality of life and therefore higher adherence to DOACs they are more 
likely to concord with DOAC treatment resulting in successful treatment, fewer complication 
of stroke or VTE and reduced mortality. Incorporating shared-decision making processes into 
consultations is the optimal approach to achieve maximum patient satisfactionand improved 
QoL 60.  
Warfarin, although an inexpensive drug, requires costly monitoring and is resource intensive 
which patients are known to dislike due to the regular clinic appointments and blood tests 
with up to 13 appointments a year and less than 65% of time spent in therapeutic range with 
a consequent increase in risk of stroke 62. DOAC on the other hand are costly drugs and this 
has been a nature of debate in order to achieve the most cost-effective anticoagulant 
treatment available on the NHS.  
Cost effectiveness of DOACs is highly dependent and directly related on the costs of the 
alternative, VKA, with the associated adequate quality of monitoring and therapeutic control 
63. However, this can be balanced with the enhanced patient preference of no monitoring 
with DOACs therefore indicating higher satisfaction, preference and overall QoL with DOACs.  
Possible Weaknesses  
This review comprised of a comprehensive literature search and extensive scrutiny of relevant 
articles for inclusion in order to minimise the risk of bias. However, meta-analysis and robust 
conclusions cannot be drawn because of significant heterogeneity in validated tool utilised, 
outcome measures, and publication bias. Overall, this review had several limitations that may 
affect its generalisability, including language bias (only English-language databases and 
journals were searched), selection bias (allocation concealment), and detection bias or 
performance bias (blinding related). Blinding of all study participants, personnel, and 
outcome assessors was not possible across all included studies because of the nature of the 
outcomes reported and study design (real world observational studies). Patients and 
professionals participating the in the studies were aware of the nature of the study carried 
out and intention behind completing the questionnaires chosen. Moreover, reporting bias 
cannot be ruled out. Finally, a limitation of PROs, is that they exclude patient with disability 
or low literacy skills and therefore may not be representative of the patient population or 
present an accurate picture of patient acceptance of treatment therefore further work needs 
to be performed to ensure inclusion of these patient groups 64. 
 
Conclusions  
This review has established that the majority of patients are satisfied and would therefore 
prefer anticoagulation with DOACs when compared to warfarin for VTE and AF treatment and 
long term prevention of stroke. This has been identified by the increased satisfaction, 
adherence and HRQoL experienced by patients on DOACs which is likely to have substantial 
impact on the NHS burden, incidence of stroke complications and overall reduction in 
morbidity and mortality. However, heterogeneity in the analysed studies (randomised and 
observational studied) does not allow firm conclusions and statistical inference (meta-
analysis). More original work should be carried out to strengthen this evidence.  
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Table 1: Summary of controlled trials and observational studies 
 
 Author -
year of 
publication 
Data 
collection 
period 
 Treatment/ 
Population 
Study details PRO Assessment Sample size Outcomes 
measured 
Main findings of the 
study 
Patients with Atrial Fibrillation  
Monz et al – 
2013 25 
December 
2005 to 
December 
2007 
Treatment: 
Dabigatran versus 
dose adjusted 
warfarin 
Population: for 
non-valvular AF 
Mean age: 71.5 
years 
Female: 36.4%  
Design: RCT 
Subgroup of RE-LY 
population RE-LY = 
Prospective, 
randomised open-
label, blinded end 
point evaluation 
Setting: 44 
countries and 951 
clinical centres 
Patient reported 
health related 
quality of life using 
EQ-5D utility and 
visual analogue VAS 
scores, assessed at 
baseline, 3 and 12 
months 
1435 patients 
(497 in 
dabigatran 110mg 
BD, 485 
dabigatran 150mg 
BD group and 453 
warfarin group) 
Changes in HRQol 
over time 5 
questions on 5 
dimensions of 
health (mobility, 
self-care, usual; 
activities, 
pain/discomfort, 
anxiety/ 
depression) and 3 
levels of response  
HRQoL: No statistically 
significant difference between 
dabigatran groups or warfarin 
groups  
Utility weighted scores for 
Dabigatran 150mg BD ranged 
from 0.805 to 0.811 for 
dabigatran  110mg BD and did 
not change over the 1-year 
observation period. No 
difference between dabigatran 
and warfarin group except 
dabigatran 150mg at 3 months. 
None of the in-groups or 
between-group analyses were 
significant 
Hohnloser et 
al – 2015 28 
October 
2012 - 
September 
2013 
Treatment: 
Rivaroxaban vs 
standard therapy 
for cardioversion 
Population: 
Patients with AF 
requiring 
cardioversion 
Design: RCT Post 
hoc study of X-VERT 
trial, setting: 
conducted in 7 
countries 
US, UK Canada, 
Netherlands, 
Patient reported 
treatment 
satisfaction using 
User Treatment 
Satisfaction 
Questionnaire for 
medication Version 
II, completed after 
705 patients 
completed the 
questionnaire 
11 items, 4 
subscales 
convenience, 
effectiveness, 
global satisfaction 
and side effects 
based on Likert 
scales 
Satisfaction: Rivaroxaban group 
reported increased score for 
convenience (81.74 vs 65.78), 
effectiveness (39.41 vs 32.95) 
and global satisfaction (82.07 vs 
66.74), p<0.0001.  
Age range: 18 – 
65 years 
Female: 52.7%  
France, Germany 
and Italy  
42 days of 
treatment 
Coleman et al 
– 2016 29 
 Treatment: 
Rivaroxaban for 
stroke prevention 
Population: 
Patients with 
non- valvular AF 
prescribed 
rivaroxaban  
Mean age: 71 
years 
Female: 36.3%  
Design: non-
randomised 
controlled trial 
Xantus ACTS sub 
study 
prospective 
international non- 
interventional 
phase 4 study, 
Setting: 308 
investigational sites 
in 21 countries 
Patient reported 
treatment 
satisfaction using 
ACTS implemented 
at baseline and 3 
months after 
switch 
1291 patients 
with prior 
warfarin 
treatment 
switched to 
rivaroxaban  
12 item burden 
scale (max 60 
points) and 3 item 
benefits scale (max 
15 points 
Satisfaction: 
Baseline ACTS burden and 
benefit scores 50.51 and 10.30 
respectively, scores improved 
after 3 months to 54.5 and 11.4 
respectively 
Koretsune et 
al – 2017 30 
September 
2015 to 
October 
2016 
Treatment: 
patients switched 
from warfarin to 
apixaban 
Population: 
Patients with 
non-valvular AF 
Mean age: 76 
years  
Female: 37.9% 
Design: RCT 
Prospective short 
term multicentre 
single arm 
observational study 
AGAIN study 
Setting: 149 
institutions in Japan 
 Patient reported 
treatment 
satisfaction using 
ACTS, implemented 
before switch and 
after 12 weeks of 
treatment with 
apixaban 
697 patients 
switched to 
apixaban 
12 item burden 
scale (max 60 
points) and 3 item 
benefits scale (max 
15 points) 
Satisfaction: No significant 
changes in ACTS benefit scores 
(10.5 vs 10.4) but significant 
changes in ACTS burden scores 
vs baseline (55.6 vs 49.7, 
p<0.0001) 
Alegret et al – 
2014 31 
1st February 
to 30th June 
2012 
Treatment: on 
VKA or NOAC 
Population: 
Patients with AF 
undergoing 
Design: Prospective 
study 
Patients included in 
the CARDIOVERSE 
study 
Patient reported 
HRQoL in patients 
on oral 
anticoagulants 
using Sawicki 
Questionnaire, 
416 patients. 351 
in VKA group and 
65 in DOAC (59 
on dabigatran 
and 5 in 
32 items grouped in 
5 dimensions. 
patients score on 
scale of 1-6 to 
determine their 
HRQoL: No significant 
differences seen at baseline 
between the 2 groups. At 
baseline general treatment 
satisfaction score was 
significantly lower in the NOAC 
electrical 
cardioversion  
mean age: 62 
years 
Female:  19%  
Setting: conducted 
in 67 hospitals in 
Spain 
assessed at 
baseline and 6 
months 
rivaroxaban) 
group.  
At 6 months 215 
in VKA group and 
37 in NOAC group 
completed the 
questionnaire   
treatment related 
quality of life 
group (better HRQoL). Global 
score was also lower indicating 
better HRQoL in NOAC group 
(10.3 vs 9.6). No significant 
differences seen at 6 months 
between the 2 groups.  
Hanon et al – 
2016 38 
April 2013 to 
June 2014 
Treatment: 
patients 
previously treated 
with warfarin and 
switched to 
rivaroxaban 
Population: Non 
valvular AF 
patients 
Mean age: 74.8 
years 
Female: 37%  
Design: 
Prospective, 
observational study 
Setting: conducted 
in French 
multicentre 
 Patient reported 
treatment 
satisfaction using 
ACTS, administered 
at baseline, 1, 3 
and 6 months 
405 patients 
switched to 
rivaroxaban 
A validated 15 item 
patient reported 
scale including 12 
item ACTS burdens 
scale and 3 item 
ACTS benefits scale 
Satisfaction: At 3 months, 
statistically significant patient 
satisfaction with rivaroxaban 
compared with VKA warfarin. 
Mean ACTS burden score (46.5 
vs 54.9, p<0.001) & benefit scale 
(10.4 vs 10.9, p<0.001) between 
rivaroxaban & VKA 
Marquez-
Contreras et al 
2016 41 
May 2013 to 
April 2015 
Treatment: 
patients on 
rivaroxaban 
Population: 
Patients with non 
valvular atrial 
fibrillation 
Mean age – 75 
years 
Female: 50.3%  
Design: 
Observational, 
prospective, 
multicentre, 
longitudinal study 
Setting:  conducted 
in 160 primary and 
specialty care 
centres in Spain 
Patient reported 
quality of life using 
Sawicki 
Questionnaire, 
administered at 
baseline and at 6 
and 12 months  
370 included in 
the study 
Sawicki 
questionnaire= 32 
items grouped in 5 
dimensions. 
General treatment 
satisfaction, self-
efficacy, strained 
social network, 
daily hassles and 
distress 
HRQoL: Global compliance was 
84.1% and 80.3% at 6 and 12 
months respectively. Average 
QoL rating was 112.85 in non-
compliant and 111.80 in the 
compliant group (p >0.05). After 
12 months 124.67 in non-
compliant group and 83.47 in 
the compliant group (p<0.0001) 
showing a significantly 
improved QoL.  
Keita et al – 
2017 33 
July 2014 to 
July 2015 
Treatment: 
patients 
prescribed 
warfarin or 
switched to DOAC 
or initiated on 
DOAC treatment 
Population: VTE 
patients 
Mean age: 60.4 
years 
Female: 46%  
Design:  
Observational 
descriptive study, 
Setting: conducted 
in multicentre in 
France 
Patient reported 
adherence, 
satisfaction and 
quality of life using 
Morisky Medication 
Adherence Scale, 
MMAS-8, EQ-5D, 
perception of 
anticoagulation 
questionnaire part 
2, administered 
after 3 months 
treatment and 6 
months treatment 
100 patients 50 in 
warfarin group 
and 50 in DOAC 
group 
EuroQol 5D 
questionnaire (5 
dimensions, 
mobility, 
autonomy, usual 
activities, 
pain/discomfort, 
anxiety/ 
depression) with 3 
response levels. 
PACT-Q2 to assess 
treatment 
satisfaction - 3 
domains, practical 
aspects 
satisfactions and 
adherence. MMAS-
8- 8 item 
questionnaire  
HRQoL: VKA patients reported 
more negative experience than 
DOAC group in EQ-5d 
questionnaire. No significant 
difference in overall quality of 
life in favour of DOAC group (71 
vs 65, p<0.063).  
Satisfaction: Satisfaction with 
PACT-Q2 >90% of patients were 
satisfied with their VKA or DOAC 
treatment.  
Adherence: Adherence with 
MMAS-8 7.2 in VKA group vs 7.7 
in DOAC group greater 
adherence in DOAC group 
especially after 6 months 
treatment.  
Contreras 
Muruaga et al 
2017 42 
September 
2014 to 
March 2015 
Treatment: 
Population: 
patients with 
non-valvular atrial 
fibrillation 
Mean age: 75 
years 
Female: 44.2% 
Design: 
observational 
cross-sectional 
study 
Setting: 63 
neurology 
departments in 
Spain 
Patient reported 
satisfaction, QoL 
and perceptions of 
VKA versus DOACs 
(only QoL included)  
1337 patients 
587 patients 
DOAC 
750 patients VKA 
EuroQol 5 
Dimensions 3 level 
questionnaire and 
visual acuity score 
HRQoL: mean EQ-5D 3L score 
was 75.9  
Patients taking VKA with longer 
time in therapeutic range were 
more satisfied.  
DOAC = 76.26 & VKA = 75.05 – 
showing no significant 
difference in HRQoL. HRQoL for 
all 3 DOACs were comparable 
Stephenson et 
al 2018 35 
October 
2011 to June 
2014 
Treatment: 
patients 
prescribed 
warfarin, 
Design: Hybrid US 
observational study 
Patient reported 
adherence using 
Morisky Medication 
675 patients  
271 in warfarin 
group 
Validated patient 
reported tool. 
Measures 
medication taking 
Adherence: Mean MMAS scores 
were similar among all 4 groups 
in the initial and follow up 
surveys 
dabigatran, 
rivaroxaban or 
apixaban 
Population: 
Patients with 
non-valvular AF 
Mean age: 65.6 
years 
Female: 39.4%  
Setting: conducted 
in 14 institutions in 
the US 
Adherence Scale 
MMAS-8  
duke 
anticoagulation 
treatment scale, 
administered at 
baseline, and at 4, 
8 and 12 months 
266 dabigatran 
group 
128 rivaroxaban 
group 10 in 
apixaban group 
behaviours and 
explores 
circumstance 
influencing 
adherence. Scores 
0 to 8 
DASS score 4 points 
to measure QOL 
and satisfaction 
among OAC 
treatment  
Satisfaction: DASS scored were 
lower for dabigatran and 
rivaroxaban cohort indicating 
greater treatment satisfaction 
de Caterina et 
al – 2018 36 
2012 to 
2013 
Treatment: on 
stable VKA or 
switched to NOAC 
(rivaroxaban, 
dabigatran or 
apixaban) 
Population: 
Patients with 
atrial fibrillation 
Mean age: 72 
years  
Female: 37%  
Design: prospective 
study PREFER in AF 
Registry Sub study 
Setting: conducted 
in 7 European 
countries 
Patient reported 
quality of life and 
satisfaction using 
PACT- Q2 and EQ-
5D-5L 
questionnaires, 
administered at 
baseline and at 1 
year follow up 
2950 patients 
completed the 
questionnaires, 
excluded patients 
stable on NOAC. 
2102 patients on 
stable treatment 
with VKA, 213 
patients switched 
from VKA to 
NOAC   
PACT Q2 questions 
about satisfaction 
EQ-5D-5L questions 
investigates several 
aspects of QoL.  
Satisfaction: Switched patients 
more often reported bruising or 
bleeding, dissatisfaction with 
treatment, mobility problems 
and anxiety/ depression traits 
with VKA that may have 
influenced the switch to NOAC.  
Koretsune et 
al – 2018 39 
April 2012 Treatment: 
Rivaroxaban in 
patients 
previously on 
warfarin 
Population: non-
valvular AF 
patients 
Design: post 
marketing 
surveillance study 
of a prospective 
study 
Setting:  conducted 
at 124 sites in 
Japan 
Patient reported 
treatment 
satisfaction ACTS  
and Treatment 
satisfaction 
questionnaire for 
Medication Ver II, 
administered at 
665 patients 
included in the 
study 
ACTS Burden and 
Benefits   
TSQM Ver II 
Satisfaction: Statistically 
significant improved  
TSQM scores in the rivaroxaban 
group at moth 3 and 6 compared 
to baseline in all 4 domains 
(p<0.001). 
Significantly (p<0.001) less 
burden at 3 months (54.6) and 
month 6 (54.5) vs baseline 
Mean age: 73.6 
years 
Female: 35.5%  
baseline and at 3 
and 6 months 
(51.0), and benefit remained 
stable in the rivaroxaban group 
Larochelle et 
al – 2018 40 
February 
2013 to 
December 
2014 
Treatment: 
Patients newly 
prescribed an oral 
anticoagulant 
(either warfarin 
or DOAC, 
apixaban, 
rivaroxaban or 
dabigatran) 
Population: 
Patient with non 
valvular atrial 
fibrillation 
Mean age: 71.35 
years 
Female: ~60%  
Design: Prospective 
observational study 
Setting:  conducted 
in hospitals in 
Canada 
Patients 
expectations and 
satisfaction with 
oral 
anticoagulation 
treatment using 
PACT Q1 and PACT 
Q2 questionnaires, 
administered 
before treatment 
and at 3 and 6 
months post 
discharge 
159 patients 
included (71 on 
warfarin and 88 
on DOAC mainly 
rivaroxaban) 
PACT Q = 
Perception of 
Anticoagulant 
Treatment 
Questionnaire 
Q1= 7 questions on 
patient 
expectations 
Q2 = 20 questions 
on treatment 
convenience, 
burden of disease 
and treatment and 
anticoagulant 
treatment 
satisfaction. 
Expectations: No significant 
differences in treatment 
expectations, patients 
prescribed warfarin had a 
slightly higher expectation of 
having side effects.  
Satisfaction: Convenience 
scores were similar at 3 months 
but much higher in DOAC group 
at 6 months (86.29 vs 90.97, 
p<0.05). Satisfaction scores 
were similar between both 
groups.  
Benzimra et al 
– 2018 32 
June 2013 to 
November 
2015 
Treatment: 
Patients receiving 
oral 
anticoagulants 
VKA/ DOAC 
(dabigatran, 
rivaroxaban or 
apixaban), or 
switched 
treatments 
Population: 
patient with atrial 
fibrillation 
Design: Real life 
observational 
descriptive cross-
sectional study 
Setting: conducted 
in various 
recruitment sites in 
France 
Quality of life, 
treatment 
satisfaction and 
adherence using 3 
validated 
questionnaires-  
Euro-QoL 5 
dimensions 3 levels 
visual analog scale 
EQ-5D, Perception 
of Anticoagulation 
Treatment 
Questionnaire 
200 patients (89 
on VKA, 52 on 
DOAC, 50 
switched to 
DOAC, 9 switched 
to VKA) 
EQ-5D - 5 
dimensions 
mobility, self-care, 
usual activities, 
pain/discomfort 
and anxiety/ 
depression. Score 
0-100 
PACT-Q2 assess 
treatment 
satisfaction with 
anticoagulant 
assesses 
HRQoL: HRQoL - EQ-5D scores 
were similar in all groups but 
higher in the DOAC group. 
Overall QoL on the EQ-5D VAS 
tended to be better in the DOAC 
group but this was not 
statistically significant.  
Satisfaction: Convenience and 
satisfaction scores were high in 
all 3 groups but significant 
difference in favour of the DOAC 
group (p<0.001)  
Mean age: 74.3 
years 
Female: 41%  
PACT-Q2, 8 item 
Morisky Scale 
Medication 
Adherence Scale 
MMAS-8, 
administered once 
over the phone to 
patients for at least 
3 months 
treatment 
convenience, 
burden and 
satisfaction.  
 
MMAS-8 assesses 
adherence to 
therapy through 8 
questions.  
Adherence: Adherence scores 
were high for all 3 groups with 
no significant difference 
between the groups.  
Okumura et al 
2018 43 
Sept 2013 
and 
December 
2015 
Treatment: 
patients on 
anticoagulation 
(VKA/ DOAC)  
Population: 
Patients with non 
valvular atrial 
fibrillation 
Mean age – 72 
years 
Female: 22.6%  
Design: Sub study 
of SAKURA AF 
registry  
Questionnaire 
based prospective 
study 
Setting:  conducted 
in 40 institutions in 
Japan 
Patients 
satisfaction with 
anticoagulant 
treatment using 
ACTS and 
Treatment 
Satisfaction 
questionnaires for 
medication II, 
administered once 
1475 patients -
654 DOAC group 
(241 dabigatran, 
331 rivaroxaban 
and 1 edoxaban) 
& 821 patients in 
warfarin group. 
513 completed 
the ACTS 
questionnaire  
ACTS – 17 item 
questionnaire to 
measure patient 
satisfaction 
addressing burden 
and benefits. The 
TSQM II covers 4 
domains, 
effectiveness, side 
effects, 
convenience and 
global satisfaction.  
Satisfaction: There were no 
significant differences in the 
TSQM II questionnaire between 
the 2 groups. The ACTS burden 
scores were significantly higher 
for the DOAC group than the 
warfarin group showing greater 
satisfaction with treatment.  
Fernandez et 
al – 2018 37 
ALADIN 
Study: 
September 
2014 to 
March 2015 
ESPARTA 
Study:  
October 
2015 to 
March 2016 
Treatment: 
patients 
prescribed VKA or 
DOAC 
Population: 
Patients with 
non-valvular AF  
Mean age: 78.5 
years 
Female: 48.95%  
Design: 2 different 
cross-sectional 
studies combined 
(ALADIN and 
ESPARTA studies), 
Setting: conducted 
at various 
departments in 
Spain 
Patient satisfaction 
with anticoagulant 
treatment using 
ACTS 
questionnaire, 
administered at 
regular single visit, 
patients on at least 
3 months 
treatment  
ALADIN study: 
472 patients  
ESPARTA study: 
837 patients.  
1309 patients in 
total, 902 VKA 
group ad 407 
DOAC group 
ACTS is patient 
reported measure 
of satisfaction with 
anticoagulation .12 
items that assess 
perceived burdens, 
4 items to assess 
perceived benefits,  
Satisfaction: Overall satisfaction 
with oral anticoagulation was 
high. Patients taking DOACs 
showed a lower perceived 
burden with anticoagulation 
therapy (48.8 vs 53.1, p<0.001).  
Perceived benefits were higher 
in DOAC group (11.06 vs 11.99, 
p<0.001).  
Obamiro et al 
– 2018 34 
Not 
specified  
Treatment: 
prescribed oral 
anticoagulants 
Population: 
Patients with 
atrial fibrillation 
Age Range – 18- 
>65 years 
Female: 68%  
Design: Secondary 
analysis of the 
Australian oral 
anticoagulation 
survey  
Setting: conducted 
through online 
recruitment in 
Australia 
Predictors of 
adherence and 
patient related 
factors of 
adherence using 
Morisky Medication 
Adherence Scale 
(MMAS-8), 
anticoagulation 
knowledge tool and 
PACT Q1 and Q2 
questionnaires 
386 patients  
(Warfarin: 100 
patients, 
apixaban: 121 
patients, 
rivaroxaban: 123 
patients, 
dabigatran: 42 
patients) 
MMAS-8 to assess 
levels of 
adherence.  
AKT to assess OAC 
knowledge & 
Perception of 
anticoagulation 
treatment 
questionnaires 
assessing 
treatment 
expectation, global 
convenience and 
satisfaction.  
Adherence: No significant 
difference in adherence seen 
between patients taking 
warfarin and DOACs. Patients in 
the high adherence group 
showed a higher anticoagulation 
knowledge.  
Satisfaction: Satisfaction scores 
were greater in the medium 
adherence groups.  
Paitents with VTE (PE and DVT) 
Bamber et al 
2013 26 
March 2007 
to Sept 2009 
Treatment: 
Rivaroxaban vs 
enoxaparin/ 
warfarin for 
Population: 
patients with DVT  
Mean age: 56.8 
years 
Female: 42.4%  
Design: RCT 
Sub-study analysis 
of EINSTEIN DVT 
study 
Setting: Conducted 
in 7 countries (US, 
UK, Canada, 
Netherlands, 
France, Germany 
and Italy) 
Patient reported 
treatment 
satisfaction using 
ACTS score, 
assessed at 12 
months of 
treatment 
1472 patients ACTS 15-point 
score Burden and 
Benefits 
Satisfaction: 
Clinically significant reduction in 
ACTS burden (55.2 vs 52.6, 
p<0.0001) and improvement in 
ACTS benefit (11.7 vs 11.5, 
p=0.006) in rivaroxaban group 
(compared with warfarin) 
Prins et al – 
2014 27 
March 2007 
- March 
2011 
Treatment: 
Rivaroxaban vs 
standard therapy 
(enoxaparin/ 
warfarin) 
Design: Sub 
analysis of EINSEIN 
PE study, setting:  
conducted in 7 
countries 
Patient reported 
treatment 
satisfaction using 
ACTS and 
Treatment 
satisfaction 
2397 patients 
(1200 in 
rivaroxaban arm 
and 1197 in 
enoxaparin/ 
warfarin arm) 
ACTS 15 point scale 
Burden Scale and 
Benefit scale  
Satisfaction: Rivaroxaban group 
reported statistically significant 
increase in ACTS benefit (11.9 vs 
11.4, p<0.0001) and less ACTS 
burden (55.4 vs 51.9, p<0.0001)   
 
Population: 
patient with PE 
Mean age: 58 
years 
Female: 44%  
US, UK Canada, 
Netherlands, 
France, Germany 
and Italy 
questionnaire for 
Medication Ver II, 
assessed at 1, 2, 3, 
6 and 12 months 
Statistically significant improved 
TSQM II scores in the 
rivaroxaban group p<0.0001 for 
all 4 factors, effectiveness, side-
effects, convenience and global 
satisfaction 
 
Carrothers et 
al – 2014 44 
May 2010 to 
December 
2011 
Treatment: 
Patients 
prescribed 
rivaroxaban 
Population: VTE 
prophylaxis 
following lower 
limb arthroplasty 
Mean age: 66 
years  
Female: 61%  
Design: Prospective 
study 
Setting: conducted 
in single 
orthopaedic centre 
in Canada 
Patient reported 
compliance using 
Self-administered 
questionnaire, 
administered 14 
days post-surgery 
and 6 weeks after 
treatment at the 
follow up 
appointment  
2621 patients 
attended the 6 
week 
appointment 
Yes / no 
Questionnaire 
developed by the 
investigators to 
measure 
adherence/ 
compliance,  
Compliance: Majority of 
patients were compliant with 
rivaroxaban treatment (83%), 
non-compliance was associated 
with older age, smaller BMI and 
lower preoperative 
haemoglobin.  
Patients with AF and VTE 
Castellucci et 
al -  2015 47 
September 
2012 - 
September 
2013 
Treatment: 
Patients on oral 
anticoagulants 
(VKA, 
rivaroxaban, 
dabigatran and 
apixaban)  
Population: VTE 
and AF patients 
Mean age: 63 
years 
 Female: 42.7%  
Design: Cross-
sectional survey 
Setting: conducted 
in 1 anticoagulant 
clinic in Canada 
Self-reported 
anticoagulant 
adherence using 4 
item Morisky score, 
administered once 
500 patients (367 
on VKA, 130 on 
DOACS)  
4-item Morisky 
Adherence Scale 
used  
Adherence: Self-reported 
adherence using the 4 item 
Morisky scale was 56.2% on VKA 
and 57.1% on DOAC. Adherence 
was similar in both groups.  
 Table 2: Risk of Bias Assessment (Cochrane RCTs) for Controlled Trials 
+  = low risk of bias 
 - = high risk of bias 
? = unclear risk of bias 
 
 
 
Random 
sequence 
generation 
Allocation 
Concealment 
Binding-
participants 
and 
personnel 
Binding-
outcome 
assessment 
Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Bamber et al 2013 + + ? ? + + 
Coleman et al 2016 - - - - + + 
Hohnloser et al 2015 + - - - + + 
Koretsune et al 2017 + - - - + + 
Monz et al 2013 + + + + + + 
Prins et al 2015 + + + - - - 
Table 3: Newcastle-Ottawa Quality Assessment Scale and analysis of observational studies 
 
Sample 
Representativeness 
Sample size 
Non-
respondents 
Ascertainment 
of exposure 
Comparability 
Assessment 
of outcome 
Statistical 
test 
Alegret et al 2014 selected * * ** * * * 
Benzimra et al 2018 selected * * ** * * * 
Carrothers et al 2014 Selected * * - * * - 
Castellucci et al 2015 Selected * * ** * * * 
De Caterina et al 2018 Selected * - ** * * - 
Fernandez et al 2018 Selected * * ** * * - 
Hanon et al 2016 * * - ** * * - 
Keita et al 2017 selected * * ** * * * 
Koretsune et al 2018 Selected * * ** * * - 
Larochelle et al 2018 Selected * - ** * * * 
Marquez-Contreras et al 2017 * * * * * * - 
Muruaga et al 2017 selected * - ** * * * 
Obamiro et al 2018 * * * ** * * * 
Okumura et al 2018 Selected * - ** * * * 
Stephenson et al 2018 * * * ** * * * 
7-8 * = good studies 
5-6 * = satisfactory studies 
0-4 * = unsatisfactory studies 
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